NasdaqGS:SGMO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Sangamo Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SGMO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.8%

SGMO

6.6%

US Biotechs

1.8%

US Market


1 Year Return

1.1%

SGMO

31.5%

US Biotechs

14.2%

US Market

Return vs Industry: SGMO underperformed the US Biotechs industry which returned 31.5% over the past year.

Return vs Market: SGMO underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

SGMOIndustryMarket
7 Day6.8%6.6%1.8%
30 Day-11.8%-0.9%0.04%
90 Day22.2%-1.8%9.8%
1 Year1.1%1.1%33.7%31.5%16.7%14.2%
3 Year-21.6%-21.6%18.4%12.7%41.6%32.2%
5 Year69.0%69.0%16.2%8.2%90.9%69.5%

Price Volatility Vs. Market

How volatile is Sangamo Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sangamo Therapeutics undervalued compared to its fair value and its price relative to the market?

2.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SGMO ($10.78) is trading above our estimate of fair value ($0.87)

Significantly Below Fair Value: SGMO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SGMO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SGMO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGMO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGMO is good value based on its PB Ratio (3x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Sangamo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

46.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGMO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGMO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGMO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGMO's revenue (30.8% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: SGMO's revenue (30.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGMO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sangamo Therapeutics performed over the past 5 years?

-18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SGMO is currently unprofitable.

Growing Profit Margin: SGMO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SGMO is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare SGMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: SGMO has a negative Return on Equity (-19.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sangamo Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SGMO's short term assets ($679.4M) exceed its short term liabilities ($93.9M).

Long Term Liabilities: SGMO's short term assets ($679.4M) exceed its long term liabilities ($289.5M).


Debt to Equity History and Analysis

Debt Level: SGMO is debt free.

Reducing Debt: SGMO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SGMO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SGMO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 21.5% per year.


Next Steps

Dividend

What is Sangamo Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGMO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGMO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Sandy Macrae (57 yo)

4.25yrs

Tenure

US$3,986,555

Compensation

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch.B, Ph.D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019. Dr. Macrae has been the Chief Executive Office ...


CEO Compensation Analysis

Compensation vs Market: Sandy's total compensation ($USD3.99M) is about average for companies of similar size in the US market ($USD4.56M).

Compensation vs Earnings: Sandy's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director4.25yrsUS$3.99m0.019%
$ 286.3k
Sung Lee
Executive VP & CFO0.92yrUS$2.53mno data
Gary Loeb
Executive VP1yrUS$2.28mno data
R. Ramelmeier
Executive Vice President of Technical Operations2.5yrsUS$1.10m0.0041%
$ 62.5k
Prathyusha Duraibabu
VP of Finance & Principal Accounting Officer1.25yrsno data0.0014%
$ 21.6k
McDavid Stilwell
Senior Vice President of Corporate Communications & Investor Relations3.83yrsno datano data
Nathalie Dubois-Stringfellow
Senior Vice President of Product Development & Management1.67yrsno datano data
Heather Erickson
Chief of Staff4.17yrsno datano data
Duncan McKay
Senior VP & GM of Europe0.92yrno datano data
Jason Fontenot
Senior Vice President of Cell Therapy & Interim Head of Research1.5yrsno datano data
Bettina Cockroft
Senior VP & Chief Medical Officer1yrno datano data
Melita Jung
Senior VP & Head of Business Developmentno datano datano data

1.5yrs

Average Tenure

50yo

Average Age

Experienced Management: SGMO's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Alexander Macrae
CEO, President & Director4.25yrsUS$3.99m0.019%
$ 286.3k
Kenneth Hillan
Head of Therapeutics of 23&Me and Directorno datano datano data
H. Parker
Independent Chairwoman of the Board3.25yrsUS$203.81k0.0092%
$ 140.1k
Stephen Dilly
Independent Director10.5yrsUS$161.31k0.0071%
$ 107.8k
Mark Chee
Member of Scientific Advisory Board0.83yrno datano data
Robert Carey
Independent Director4.25yrsUS$176.31k0.0036%
$ 54.0k
Joseph Zakrzewski
Independent Director3.25yrsUS$177.56k0.021%
$ 323.4k
Roger Kornberg
Member of Scientific Advisory Board0.83yrno datano data
Jef Boeke
Member of Scientific Advisory Board0.83yrno datano data
Sona Ramasastry
Independent Director8.25yrsUS$166.31k0.0036%
$ 54.0k
Karen Smith
Independent Director2.25yrsUS$161.94k0.0030%
$ 45.0k
Megan Levings
Member of Scientific Advisory Board0.83yrno datano data

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: SGMO's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.


Top Shareholders

Company Information

Sangamo Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sangamo Therapeutics, Inc.
  • Ticker: SGMO
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.520b
  • Shares outstanding: 140.99m
  • Website: https://www.sangamo.com

Number of Employees


Location

  • Sangamo Therapeutics, Inc.
  • 7000 Marina Boulevard
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SGMONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2000
GBYDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2000
GBYXTRA (XETRA Trading Platform)YesCommon StockDEEURApr 2000
0R1DLSE (London Stock Exchange)YesCommon StockGBUSDApr 2000

Biography

Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 05:56
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.